Lindbrook Capital, LLC Viking Therapeutics, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 546 shares of VKTX stock, worth $35,965. This represents 0.0% of its overall portfolio holdings.
Number of Shares
546
Previous 265
106.04%
Holding current value
$35,965
Previous $14,000
142.86%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding VKTX
# of Institutions
478Shares Held
66.1MCall Options Held
6.24MPut Options Held
3.01M-
Vanguard Group Inc Valley Forge, PA10.1MShares$665 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$397 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$337 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$148 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$122 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.05B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...